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Background: The MRE11, RAD50, and NBN genes encode proteins of the MRE11-RAD50-NBN (MRN) complex
involved in cellular response to DNA damage and the maintenance of genome stability. In our previous study we
showed that the germline p.I171V mutation in NBN may be considered as a risk factor in the development of
childhood acute lymphoblastic leukemia (ALL) and some specific haplotypes of that gene may be associated with
childhood leukemia. These findings raise important questions about the role of mutations in others genes of the
MRN complex in childhood leukemia. The aim of this study was to answer the question whether MRE11 and RAD50
alterations may be associated with childhood ALL or AML.
Methods: We estimated the frequency of constitutional mutations and polymorphisms in selected regions of MRE11,
RAD50, and NBN in the group of 220 children diagnosed with childhood leukemias and controls (n=504/2200). The
analysis was performed by specific amplification of region of interest by PCR and followed by multi-temperature
single-strand conformation polymorphism (PCR-MSSCP) technique. We performed two molecular tests to examine
any potential function of the detected the c.551+19G>A SNP in RAD50 gene. To our knowledge, this is the first
analysis of the MRE11, RAD50 and NBN genes in childhood leukemia.
Results: The frequency of either the AA genotype or A allele of RAD50_rs17166050 were significantly different in
controls compared to leukemia group (ALL+AML) (p<0.0019 and p<0.0019, respectively). The cDNA analysis of AA
or GA genotypes carriers has not revealed evidence of splicing abnormality of RAD50 pre-mRNA. We measured the
allelic-specific expression of G and A alleles at c.551+19G>A and the statistically significant overexpression of the G
allele has been observed. Additionally we confirmed the higher incidence of the p.I171V mutation in the leukemia
group (7/220) than among controls (12/2400) (p<0.0001).
Conclusion: The formerly reported sequence variants in the RAD50 and MRE11 gene may not constitute a risk
factor of childhood ALL in Polish population. The RAD50_rs17166050 variant allele is linked to decreased ALL risk
(p<0.0009, OR=0.6358 (95%CI: 0.4854-0.8327)). Despite the fact that there is no splicing abnormality in carriers of
the variant allele but an excess of the G over the A allele was consistently observed. This data demonstrate that
some specific alternations of the RAD50 gene may be associated with childhood ALL.Background
Leukemia has the highest incidence rate among the child-
hood neoplasms [1]. A variety of factors are etiologically
involved in leukemia, not only in different cases but also
within individual cases. The contribution of inherited gen-
etic susceptibility to the development of cancer is increas-
ingly investigated.* Correspondence: m_mosor@man.poznan.pl
1Department of Molecular Pathology, Institute of Human Genetics Polish
Academy of Sciences, Strzeszyńska 32, 60-479, Poznań, Poland
Full list of author information is available at the end of the article
© 2013 Mosor et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe MRE11, RAD50, and NBN genes encode proteins
of the MRN complex involved in the repair of DNA
double-strand breaks and other critical cellular functions
including telomere maintenance, immunoglobulin class
switching, meiotic recombination and DNA damage
checkpoint activation [2]. Hypomorphic, biallelic muta-
tions in the MRE11, RAD50 and NBN genes are linked
to recessive genetic conditions, ataxia telangiectasia like
disorder (AT-LD), NBS-like and Nijmegen breakage Syn-
drome (NBS), respectively, [3-5] some of which are char-
acterized by increased risk of cancer. On the basis of theLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genomic integrity, germline heterozygous mutations af-
fecting genes of the MRN complex might play a role in
carcinogenesis. In our previous study we showed that
the germline p.I171V mutation in NBN, one of the MRN
genes, may be considered as a risk factor in the develop-
ment of childhood acute lymphoblastic leukemia [6] and
solid malignant tumors including breast cancer, larynx
and colorectal cancer in adult [7-9]. Likewise, heterozy-
gous carriers of the NBN c.657del5 mutation present in-
creased risk of malignant tumor development, especially
breast cancer [10], prostate [11], and colorectal cancer
[10]. The NBN polymorphisms, especially p.E185Q, have
been investigated in some cancer but results were incon-
clusive [12]. On the other hand some specific NBN hap-
lotypes have been related to increased susceptibility to
childhood acute leukemia [13]. These findings raise im-
portant questions about the role of mutations and poly-
morphisms in other genes of the MRN complex in the
most common malignancies in children. To date, the as-
sociation of the molecular variants in the RAD50 and
MRE11 gene with the cancer risk has not been so exten-
sively studied. Although, the germline c.687delT muta-
tion in RAD50 has been linked to sporadic breast cancer
in the Finnish population [14,15], our results excluded
the mutation as a risk variant in Polish breast cancer pa-
tients [16]. Other molecular variants in the RAD50 gene:
p.I94L in exon 3 and p.R224H in exon 5, intronic variant
IVS3-1G>A and a nonsense mutation p.Q350X in exon
7 have been observed at a low frequency not allowing to
determine whether the variants increased the risk of
breast cancer. Several missense mutations and molecular
variants of the MRE11 gene have been identified in vari-
ous tumors. Three missense mutations p.S104C, p.
R503H and p.R572Q, located at conserved positions of
the protein, have been found in breast and lymphoid tu-
mors. Additionally, an aberrant transcript without gen-
omic mutation has been found in a breast tumor [17].
Another group of researchers discovered the p.R305W
mutation in the group of 151 patients from the families
where a relative had breast cancer and/or ovarian cancer
[18]. In the same exon, the p.H302Y variant has been
reported in breast cancer [19]. To our knowledge, there
is no evidence on the association between the MRE11
and RAD50 gene mutation and childhood acute leu-
kemia. With this in mind, we decided to simultaneously
analyze the alterations in MRE11, RAD50 and NBN
genes in Polish children with acute leukemia.
Methods
Materials
Two hundred twenty blood samples were collected from
children (aged 1–18 years), who were diagnosed with
leukemia and were hospitalized at the Pediatric Oncology,Hematology and Bone Marrow Transplantation Depart-
ment in Poznań. The diagnosis of leukemia was made
according to the French-American-British criteria, after
conventional cytochemical and surface-marker analysis.
188 children were diagnosed with acute lymphoblastic
leukemia (ALL). Approximately 92% of the cases were of
the B-cell precursor type, of these, 137 patients expressed
the CD10 antigen, 25 had a pre-B immunophenotype,
12 patients had B-cell leukemia and 14 patients, T-cell
leukemia. 32 children were diagnosed with acute mye-
logenous leukemia (AML). Using the FAB criterion, 15
of the patients with AML were of M1 morphology, 9
had M2, 3 had M2/M3, and 5 had M0, M2/M3, M4 and
M5, respectively.
The leukemia group was pooled from patients from
our previous studies [6,13] and the present work. About
80% of the venous blood samples were obtained from
the patients in remission. Anonymous blood samples
collected on Guthrie cards drawn from the newborn
screening program were used as controls. The leukemia
and control samples were recruited from the ethnically
homogenous population living in the Wielkopolska
province in Poland. The DNA isolation procedure was
described in our previous study [6]. To confirm the
germline origin of the detected variant we analyzed the
DNA from oral epithelium cells.
From all patients participating in the study or from
their parents in case of minors, informed consent for
participation to permit the scientific using their samples
was obtained. The use of the anonymous Guthrie cards
as control and the study protocol were approved by the
ethics committee at the Poznan University of Medical
Sciences.
Methods
Molecular variants analysis in the MRN complex genes was
performed on DNA samples isolated from 220 children di-
agnosed with leukemia and 504 controls. All samples were
analyzed by PCR multi-temperature single-strand conform-
ation polymorphism (PCR-MSSCP) technique (Biovectis,
Warsaw, Poland). The exons 2, 5, 6, 7, 10, 13 of the
NBN gene and the exons 3, 4, 5 and 7 of the RAD50
gene were analyzed as described in our previous studies
[6,16]. Screening of the regions of the MRE11 was
performed using the primers flanking the exons 5, 9, 10,
14, 15, 19 and exon/intron boundaries (primer sequences
as Additional file 1). The selection of the screened regions
was based on the reported occurrence of the mutations in
cancer in former studies. Polymerase chain reaction prod-
ucts were mixed with loading buffer, denatured, cooled
and separated on non-denaturing polyacrylamide gel
in DNA POINTER PLUS System (Biovectis, Warsaw,
Poland) depending on PCR products or digests size. Con-
trol samples were run in parallel. Silver staining was used
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Each sample showing shifts in multi-temperature single
strand conformation polymorphism analyses was subse-
quently sequenced (OLIGO, IBB, Warszawa).
The RNA of the carriers of each genotype of the c.551+
19 G>A variant in RAD50 gene was isolated from blood
samples (QIAamp RNA Blood Mini Kit, Qiagen,
Germany) according to the manufacturer's protocol.
Genotypes were determined by a Taqman genotyping
assay (C_33291484_10) (Applied Biosytsem, Foster City,
US). RNA was reverse transcribed using the QuantiTect
Reverse Transription Kit (Qiagen, Hamburg, Germany).
The resulting cDNA pools were used for amplification
of the RAD50 gene transcripts. In order to detect tran-
scripts which may splice out exon 4 or 5 we applied the
forward primer 5′AGCCCAGATTCGTCTGCAAT and
reverse primer 5′TCTTTCGGCTATCCAAGGCT lo-
cated in exons flanking exons 4 and 5 and yielding the
602 bp PCR product. Amplification reactions were
performed in a volume of 25 μl containing AmpliTaq®
DNA Polymerase, buffer with 25 mM MgCl2 (Applied
Biosytem, Foster City, USA), deoxyribonucleotide tri-
phosphates (Sigma-Aldrich, Steinheim, Germany), pri-
mers (Oligo, Warszawa, Poland) and cDNA or genomic
DNA.
Allele-specific real time PCR was performed to compare
expression level from the reference allele and mutant al-
lele of the c.551+19G>A variant (differential allelic expres-
sion, DAE). The cDNA and genomic DNA samples
(n=30) from heterozygous carriers of the c.551+19G>A
variant were amplified with the same abovementioned
Taqman assay. The allele G and A were labeled by a differ-
ent dye and fluorescence was detected on CFX96 Touch™
Real-Time PCR Detection System (Bio-Rad, California,
USA). As standard we used a heterozygous genomic DNA
sample serially diluted of 100, 20, 4, 0.8, 0.16 and 0.03 ng
per reaction. For each sample the real time PCR was
performed in quadruple. The ratio Gquantity/Aquantity was
used to express differential allelic expression. The robust-
ness and sensitivity of this approach have been shown by
many researchers [20-22].
We used the tools available on Ensembl database (EN-
CODE: software Genomic Context and Variant Effect
Predictor) in order to carry out an in silico analysis of
the detected variants in the RAD50 gene [23-25].
Statistical analysis was performed with Fisher’s exact
test (two-tailed) or chi-square test to evaluate the statis-
tical differences in variants and polymorphisms between
the studied group and controls, depending on variant
frequency. Crude odds ratios (ORs) were calculated and
given with 95% confidence intervals (CIs). The differ-
ences were considered significant if the value of prob-
ability (p) was less than 0.05. In case of polymorphisms,
the wild-type genotype/allele served as a referencecategory. Genotype frequencies observed and expected
from the Hardy-Weinberg equilibrium were compared
with the standard chi-square test. The results from allele
specific real time PCR were analyzed using the Wilcoxon
signed-ranks test (http://www.vassarstats.net/wilcoxon.
html) to investigate whether the DAE deviated from the
null hypothesis.
Results
In the selected fragments of the RAD50 and MRE11
genes, which have been reported to harbor mutations in
cancer, we were unable to confirm the occurrence of the
formerly known mutations in our group of either ALL
or AML cases.
In the RAD50 gene we screened four coding regions
and exon-intron boundaries among leukemia patients
and 504 controls. Two missense variants (p.V315L and
p.V127I) were detected in three out of 504 controls. The
p.V127I in exon 4, detected twice, and the p.V315L in
exon 7 in the RAD50 gene, detected once, were pre-
dicted to be tolerated using the Variant Effect Predictor
(SIFT, PolyPhen) tools [23]. In addition we were able to
detect c.551+19G>A (rs17166050) single nucleotide
polymorphism in the intronic sequence of exon 4 in the
RAD50 gene. The percentage of leukemia cells in the
samples obtained from children with acute leukemia had
no impact on the detection of polymorphism. The fre-
quency of the A allele of RAD50_rs17166050 was signifi-
cantly different in the controls compared to the leukemia
group (ALL+AML) (p<0.0019) (Table 1). The frequency of
the AA and the GA genotypes was higher in controls
compared to patients with ALL (p<0.0023, OR=0.3596
(95% CI: 0.1825-0.7083) and p<0.0552, OR=0.7051 (95%
CI: 0.4929-1.009) respectively). The RAD50_rs17166050
variant allele was linked to decreased ALL risk (p<0.0009,
OR=0.6358 (95% CI: 0.4854-0.8327). Given the result and
the close localization of the rs17166050 to the donor site,
we performed a molecular test to examine whether this
substitution was causing aberrant splicing of RAD50 pre-
mRNA. For that purpose, we isolated RNA from four car-
riers of the GG genotype, four carriers of the GA genotype
and two carriers of the AA genotype. To analyze the
length of the RAD50 cDNA we performed RT-PCR. The
forward and reverse primers were complementary to
exons 3 and 6 to confirm that amplification product was
synthesized from mRNA template and not from genomic
DNA. One PCR product of the 602bp length corresponding
to correctly spliced exons 4 and 5 was synthesized in each
cDNA sample (Figure 1). Differential allelic expression
(DAE) showed that the variant allele of RAD50_rs17166050
is expressed at a significantly lower level than the wild-type
allele. All cDNA samples from heterozygous carriers of the
c.551+19G>A variant, except for one individual (no.23),
showed an excess of the reference allele over the variant
Table 1 The allele frequency distribution and results of logistic regression analysis (odds ratio OR and 95% confidence
interval CI) of the studied RAD50 c.551+19G>A gene variant in controls and acute leukemia patients
Leukemia n=220 Controls n=504 OR [95 % CI] p
Gene Variant Allele ALL AML ALL AML ALL AML
RAD50 c.551+19G>A G 285 44 671 1a 1a
A 91 20 337 0.6358 [0.4854-0.8327] 0.9104 [0.5250-1.560] 0.00091 0.7194
ALL+AML ALL+AML
RAD50 c.551+19G>A G 329 671 1a
A 111 337 0.6718 [0.5222-0.8642] 0.00191
aReference category.
1Result statistically significant (P<0.05), OR (95% CI) -Odds ratio (95% confidence interval).
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was observed (Mean ± SD, 1.32 ± 0.162534). The
Wilcoxon signed-ranks test proved the statistically signifi-
cance of the results (p<0.0001). In our leukemia groups,
the previously known sequence variants in the 3rd, 4th,
5th and 7th exon of the RAD50 were not observed.
The screening of the exon 5, 9, 10, 14, and 19 and the
flanking regions in MRE11 gene in DNA samples from
220 leukemia patients and from blood spots did not re-
veal any previously described or newly detected molecu-
lar variants.
In this study, exons 2, 3, 5, 6, 10 and 13 of the NBN
gene, in which most of the already known molecular
variants occur, were analyzed in 78 leukemia cases
(ALL=46, AML=32). We confirmed the occurrence of p.
I171V mutation in the 5th exon of the NBN gene in two
out of 32 AML cases. Because of the high frequency of
the p.I171V mutation, the control group was extended
to 2400 individuals. Taking together, the results from the
current molecular analysis of the NBN gene and theFigure 1 Analysis of RAD50 c.551+19G>A polymorphisms.
Amplification results from four different cDNA samples. Lane 1- the
wild type cDNA template. Lane 2- cDNA from the carrier of the
c.551+19G>A variant. Lane 3- cDNA from the carrier of the c.551+19G>A
variant. Lane 4-cDNA from the carrier of the AA genotype of the
RAD50_c.551+19. Lane 5-negative control. Lane 6-DNA marker
(Gene Ruler 50 bp, Fermentas).previously described mutations and polymorphisms, we
still observe a higher incidence of the p.I171V mutation
in acute lymphoblastic leukemia (5/188) than among con-
trols (12/2400). The results were statistically significant
(Table 2). The four previously described polymorphisms
of the NBN gene: c.102G>A, c.553G>C, c.1197T>C and
c.2016A>G were detected. The distributions of genotype
frequencies for each of the analyzed polymorphisms
among studied groups are shown in Additional file 2:
Table S2. Among these the CC genotype of the c.553G>C
(rs1805794) polymorphism was more frequent in leu-
kemia samples, but the results were not statistically sig-
nificant (p=0.0534).
Discussion
Our previous studies have provided evidence that the p.
I171V mutation in the NBN gene is a risk allele in acute
lymphoblastic leukemia in children and in breast, colo-
rectal, and larynx cancer in adult [6-9]. Some specific
haplotypes of the NBN gene may be associated with
childhood leukemia [13]. Therefore it was interesting to
question whether also MRE11 and RAD50 germline mu-
tations may increase the risk for childhood leukemia. So
far, no studies have addressed this subject. In the current
study we screened the selected regions, of the MRE11,
RAD50 and NBN gene, where most of already known
molecular variants occur, among 220 childhood leuke-
mia samples and controls.
In the MRE11 gene we examined the frequency of the
molecular variants in 6 exons and in the exon/intron
boundaries. Our study indicated that p.S104C, p.R503H,
p.R305W, fs.690–691 or p.R572Q were absent in our
cohort of leukemia patients or control DNA. Unfortu-
nately, no data concerning the MRE11 mutations inci-
dence in childhood leukemia have been reported to date.
Our results contradict those obtained with adult cancers.
Aberrant reduction or loss of the MRN complex due to
an MRE11 mutation has been associated with several
types of cancer including breast carcinoma, ovarian,
colorectal, gastric and prostate, leukemia and melanoma















Figure 2 The ratio of G/A alleles. Two bars represents one individual (heterozygous carrier of the c.551+ 19G>A), the red one represent ratio
of G/A in cDNA, the blue one in gDNA and data is expressed as mean±SE.
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ants. Importantly several point mutations occur on Nbs1
binding site of the hMRE11 protein, which may highlight
the significance of the MRN assembly for DNA damage
signaling and repair [29].
In the screened fragments of the RAD50 gene we
detected two molecular variants in three out of 504 con-
trols (2/504 p.V127I and 1/504 p.V315L). These mis-
sense variants have been reported previously in the UK
familial breast cancer patients (one p.V127I, two p.
V315L carriers among 435 cases) but not in controls
[15]. In our former study, the p.V127I variant was ob-
served in one out of 280 breast cancer patients and in
one individual among 328 controls [16]. The in silico
analysis did not reveal possible damaging functional ef-
fect of these two variants on the RAD50 protein. The
rare occurrence and functional evaluation of these vari-
ants suggest that none of them is a childhood leukemia
risk allele.
In the intronic sequence of the exon 4 we genotyped
the c.551+19G>A single nucleotide polymorphism. TheTable 2 Statistical analysis of the occurrence of NBN p.I171V
Leukemia n=220 Controls n=2400
Gene Mutation ALL AML
NBN p.I171V 5 2 12
ALL+AML
NBN p.I171V 7 12
1Result statistically significant (P<0.05), OR (95% CI) -Odds ratio (95% confidence intdistributions of allele frequencies for the analyzed poly-
morphism among studied groups are shown in Table 1.
The RAD50_rs17166050 variant allele was linked to
decreased ALL risk (p<0.0009, OR=0.6358 (95% CI:
0.4854-0.8327). In our previous study [16] concerning
the distribution of the c.551+19G>A in breast cancer
patients the frequency of the variant and reference allele
was similar in both groups. An association of the G
allele of the RAD50 SNP with Crohn's disease (CD) sus-
ceptibility has also been reported [30]. However, the
authors pointed out that the association of the
RAD50_rs17166050G with CD appears to be dependent
on the presence of the IGR2063 risk allele and may
therefore be a result of long-range LD in the study.
According to the Reference SNP (refSNP) Cluster Re-
port for rs17166050, MAF (Minor Allele Count) of the
A has a frequency of 16.8% in the 1000Genome phase.
Thus, individuals with the variant allele may benefit
from a protective effect against cancerogenesis. The re-
sults of the in silico analysis showed that this is the in-
tron variant of the RAD50 gene with the transcriptmutation in leukemia patients and controls
OR [95% CI] p
ALL AML ALL AML
5.437 (1.894 – 15.60) 21.60 (4.631 – 100.7) 0.00041 0.00011
ALL+AML ALL+AML
6.540 (2.547 – 16.79) 0.00011
erval).
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variant allele has any function we carried out two mo-
lecular tests on cDNA from leukemia patients (n=28)
and from healthy individuals (n=12). The first test based
on the analysis of the cDNA length in carriers of the
AA, GA, GG genotypes to check whether the variant
allele could cause aberrant splicing of the RAD50 pre-
mRNA did not reveal any abnormality of RAD50 cDNA.
In these individuals we only observed a 602bp product,
which reflected normal splicing (Figure 1). Thus, the
heterozygous GA and homozygous AA genotype of the
rs17166050 variant do not affect splicing of exon 4 and
5. With respect to intronic variant occurring in human
genome we carried out the allele specific real time PCR.
The results of the experiment showed different levels of
the expression between the reference G and variant A
allele. The results were statistically significant. cDNA
samples showed an excess of G allele over the A allele
consequently (Figure 2). The significantly altered, in a
gene dose-dependent manner, mRNA expression level
for the RAD50 gene has been reported in a study dedi-
cated to copy number alternations in adult AML ge-
nomes [31]. In childhood acute leukemia we cannot
exclude the copy number variations of the RAD50 gene
as mechanism for increasing risk. The interpretation of
the current results and explanation of the mechanism
underlying the overexpression of the G allele among
cancer patients is limited by the rather low number of
data and requires further evaluation. The screening of
the sequence variations in the 3rd, 4th, 5th and 7th exon
of the RAD50 gene pointed out that p.I94L, IVS3-1G>A,
c.687delT, p.R224H and p.Q350X were not observed in
our leukemia patients or controls. Many reports de-
scribed the contribution of the RAD50 gene variants to
breast cancer susceptibility in various populations. In
the spectrum of investigated mutations of the RAD50
gene the c.687delT is the most interesting because of
contradictory data. The mutation generates a truncated
protein without the C-terminal site and has been recog-
nized as a risk factor of familial and sporadic breast
cancer in Finnish population [14]. The occurrence of
the RAD50 687delT mutation in familial/non familial
breast cancer in Polish, UK, French and Chinese popula-
tions has not been confirmed [15,16,32,33]. Similar fre-
quency of this mutation in cancer patients and controls
and the lack of segregation with cancer suggest that it does
not increase the risk of cancer development.
Considering together our results from the current and
previous studies [6,13] of the NBN gene mutations and
polymorphisms, we still observed the higher incidence
of the p.I171V mutation in acute lymphoblastic leukemia
(5/188) than among controls (12/2400) (p<0.0004). In
this report we detected the p.I171V mutation, in the 5th
exon of the NBN gene, in two out of 32 AML cases(p<0.0001). In a recent article, Ciara et al. [34] indicated
that heterozygous carriers of the p.I171V and c.657del5
germline mutations in NBN gene may demonstrate
increased risk of childhood medulloblastoma. In our
previous study on the role of the p.I171V mutation as a
cancer risk factor for malignant solid tumors in children
we obtained contrary results [35], but owing to low
number of patients possible Type II error may have oc-
curred. On the other hand our investigation of the cells
from heterozygous carriers of the p.I171V, c.657del5 and
p.R215W mutation has showed that alone, they do not
play an essential role in carcinogenesis [36]. Among the
NBN polymorphisms, the non-synonymous c.553G>C
polymorphism (E185Q) has been the most studied, but
results have been inconsistent. In this study we observed
that variant allele of the c.553G>C NBN polymorphism
is more frequent in leukemia cases with no statistical
significance. In our previous study we have not observed
that association, probably owing to lower number of
studied patients. The number of patients can determine
the results if we are looking for any association of the
low-to-moderate cancer susceptibility gene. The c.553G>C
polymorphism has been previously evaluated in relation
to acute lymphoblastic leukemia in a Chinese population
[37]. In another study the meta-analysis has suggested that
the NBN c.553G>C variant genotypes might be associated
with an increased risk of cancer, especially in Caucasians
[12]. Yao and colleagues have excluded any association of
the abovementioned polymorphisms and breast cancer
risk in any of the populations analyzed [38]. The discrep-
ancy between reported results could be explained by ethnic
differences and a possible contribution of other variants of
the gene in different populations.
Conclusion
In conclusion, although we observed that the RAD50_rs
17166050 variant allele is linked to decreased ALL risk
(p<0.0009, OR=0.6358 (95%CI: 0.4854-0.8327)), no associ-
ation of the previously detected mutations in the RAD50
and MRE11 genes has been found. It is possible, however,
that heterozygous mutations may increase cancer risk in
cooperation with other factors including mutations in
other genes involved in DNA repair. The discrepancy be-
tween our results in childhood leukemia and other studies
in adult cancer could be explained by different gene-gene
interaction and needs further investigation.Additional files
Additional file 1: Sequences of the primers.
Additional file 2: The genotype frequency distribution and results
of logistic regression analysis (odds ratio OR and 95% confidence
interval CI) of the studied NBN gene polymorphism in controls and
leukemia patients.
Mosor et al. BMC Cancer 2013, 13:457 Page 7 of 8
http://www.biomedcentral.com/1471-2407/13/457Abbreviations
MRN: MRE11/RAD50/NBN complex; ALL: Acute lymphoblastic leukemia;
AML: Acute myelogenous leukemia; PCR-MSSCP: PCR multi-temperature
single-strand conformation polymorphism.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MM conceived the study, made substantial contributions to the conception
and design of the study, and drafted the manuscript. IZS participated in the
design of the study, performed the screening of the MRE11 gene and
sequence analysis and has been substantially involved in statistical analysis.
KN participated in screening of the genes and was involved in interpretation
of the results. ADK participated in the design of the allele specific real time
PCR and interpretation of the results. DJL has collected and selected the
patients group. JN participated in the design of the study and has been
involved in drafting and critically revising the manuscript. All authors have
read and approved the final version of the manuscript.
Acknowledgments
We are grateful to Professor Anna Grzymala-Busse from the University of
Michigan for the carefully reading of the manuscript.
Financial support
Grant from the Ministry of Sciences and Higher Education (No. N N407 201 737).
MM is supported by the stipendium from the Polish Ministry of Sciences and
Higher Education.
Author details
1Department of Molecular Pathology, Institute of Human Genetics Polish
Academy of Sciences, Strzeszyńska 32, 60-479, Poznań, Poland. 2Pediatric
Oncology, Hematology and Bone Marrow Transplantation Department,
Poznań University of Medical Sciences, Poznań, Poland.
Received: 20 September 2012 Accepted: 18 September 2013
Published: 5 October 2013
References
1. Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, Stiller CA, Coebergh JW:
Cancer in children and adolescents in Europe: developments over
20 years and future challenges. Eur J Cancer 2006, 42(13):2183–2190.
2. Assenmacher N, Hopfner KP: MRE11/RAD50/NBS1: complex activities.
Chromosoma 2004, 113(4):157–166.
3. Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG, Raams A,
Byrd PJ, Petrini JH, Taylor AM: The DNA double-strand break repair gene
hMRE11 is mutated in individuals with an ataxia-telangiectasia-like
disorder. Cell 1999, 99(6):577–587.
4. Waltes R, Kalb R, Gatei M, Kijas AW, Stumm M, Sobeck A, Wieland B, Varon R,
Lerenthal Y, Lavin MF, et al: Human RAD50 deficiency in a Nijmegen
breakage syndrome-like disorder. Am J Hum Genet 2009, 84(5):605–616.
5. Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K,
Beckmann G, Seemanova E, Cooper PR, Nowak NJ, et al: Nibrin, a novel
DNA double-strand break repair protein, is mutated in Nijmegen
breakage syndrome. Cell 1998, 93(3):467–476.
6. Mosor M, Ziolkowska I, Pernak-Schwarz M, Januszkiewicz-Lewandowska D,
Nowak J: Association of the heterozygous germline I171V mutation of
the NBS1 gene with childhood acute lymphoblastic leukemia. Leukemia
2006, 20(8):1454–1456.
7. Roznowski K, Januszkiewicz-Lewandowska D, Mosor M, Pernak M, Litwiniuk M,
Nowak J: I171V germline mutation in the NBS1 gene significantly increases
risk of breast cancer. Breast Cancer Res Treat 2008, 110(2):343–348.
8. Ziolkowska I, Mosor M, Wierzbicka M, Rydzanicz M, Pernak-Schwarz M,
Nowak J: Increased risk of larynx cancer in heterozygous carriers of the
I171V mutation of the NBS1 gene. Cancer Sci 2007, 98(11):1701–1705.
9. Nowak J, Mosor M, Ziolkowska I, Wierzbicka M, Pernak-Schwarz M,
Przyborska M, Roznowski K, Plawski A, Slomski R, Januszkiewicz D:
Heterozygous carriers of the I171V mutation of the NBS1 gene have a
significantly increased risk of solid malignant tumours. Eur J Cancer 2008,
44(4):627–630.10. Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, Nowakowska
D, Rubach M, Kosakowska E, Ruka W, et al: Increased cancer risk of
heterozygotes with NBS1 germline mutations in Poland. International
journal of cancer Journal international du cancer 2004, 111(1):67–71.
11. Cybulski C, Gorski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojc B,
Jakubowska A, Matyjasik J, Zlowocka E, Sikorski A, et al: NBS1 is a prostate
cancer susceptibility gene. Cancer Res 2004, 64(4):1215–1219.
12. Lu M, Lu J, Yang X, Yang M, Tan H, Yun B, Shi L: Association between the
NBS1 E185Q polymorphism and cancer risk: a meta-analysis. BMC cancer
2009, 9:124.
13. Mosor M, Ziolkowska I, Januszkiewicz-Lewandowska D, Nowak J:
Polymorphisms and haplotypes of the NBS1 gene in childhood acute
leukaemia. Eur J Cancer 2008, 44(15):2226–2232.
14. Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundan T,
Mannermaa A, Borresen-Dale AL, Borg A, Barkardottir RB, et al: RAD50 and
NBS1 are breast cancer susceptibility genes associated with genomic
instability. Carcinogenesis 2006, 27(8):1593–1599.
15. Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jayatilake H, Bartkova J,
Tallila J, Kaare M, Tamminen A, et al: Evaluation of RAD50 in familial breast
cancer predisposition. International journal of cancer Journal international du
cancer 2006, 118(11):2911–2916.
16. Mosor M, Ziolkowska-Suchanek I, Roznowski K, Baranowska M,
Januszkiewicz-Lewandowska D, Nowak J: RAD50 gene mutations are not
likely a risk factor for breast cancer in Poland. Breast Cancer Res Treat
2010, 123(2):607–609.
17. Fukuda T, Sumiyoshi T, Takahashi M, Kataoka T, Asahara T, Inui H, Watatani
M, Yasutomi M, Kamada N, Miyagawa K: Alterations of the double-strand
break repair gene MRE11 in cancer. Cancer Res 2001, 61(1):23–26.
18. Heikkinen K, Karppinen SM, Soini Y, Makinen M, Winqvist R: Mutation
screening of Mre11 complex genes: indication of RAD50 involvement in
breast and ovarian cancer susceptibility. J Med Genet 2003, 40(12):e131.
19. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D,
Leary RJ, Ptak J, Silliman N, et al: The consensus coding sequences of
human breast and colorectal cancers. Science 2006, 314(5797):268–274.
20. Sun C, Southard C, Witonsky DB, Olopade OI, Di Rienzo A: Allelic imbalance
(AI) identifies novel tissue-specific cis-regulatory variation for human
UGT2B15. Hum Mutat 2010, 31(1):99–107.
21. Bray NJ, O’Donovan MC: Investigating cis-acting regulatory variation
using assays of relative allelic expression. Psychiatr Genet 2006,
16(4):173–177.
22. Muller D, Rouleau E, Schultz I, Caputo S, Lefol C, Bieche I, Caron O, Nogues
C, Limacher JM, Demange L, et al: An entire exon 3 germ-line
rearrangement in the BRCA2 gene: pathogenic relevance of exon 3
deletion in breast cancer predisposition. BMC Med Genet 2011, 12:121.
23. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F: Deriving
the consequences of genomic variants with the Ensembl API and SNP
Effect Predictor. Bioinformatics 2010, 26(16):2069–2070.
24. Rosenbloom KR, Dreszer TR, Long JC, Malladi VS, Sloan CA, Raney BJ, Cline
MS, Karolchik D, Barber GP, Clawson H, et al: ENCODE whole-genome data
in the UCSC Genome Browser: update 2012. Nucleic Acids Res 2012,
40(Database issue):D912–D917.
25. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM,
Wong MC, Maddren M, Fang R, Heitner SG, et al: ENCODE data in the
UCSC Genome Browser: year 5 update. Nucleic Acids Res 2013,
41(Database issue):D56–D63.
26. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T,
Mistrik M, Aittomaki K, Blomqvist C, Heikkila P: Aberrations of the MRE11-
RAD50-NBS1 DNA damage sensor complex in human breast cancer:
MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008,
2(4):296–316.
27. Fernet M, Gribaa M, Salih MA, Seidahmed MZ, Hall J, Koenig M:
Identification and functional consequences of a novel MRE11 mutation
affecting 10 Saudi Arabian patients with the ataxia telangiectasia-like
disorder. Hum Mol Genet 2005, 14(2):307–318.
28. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, Ottini L, Crescenzi M,
Martinotti S, Bignami M, et al: Human MRE11 is inactivated in mismatch
repair-deficient cancers. EMBO Rep 2002, 3(3):248–254.
29. Park YB, Chae J, Kim YC, Cho Y: Crystal structure of human Mre11:
understanding tumorigenic mutations. Structure 2011, 19(11):1591–1602.
30. Onnie C, Fisher SA, King K, Mirza M, Roberts R, Forbes A, Sanderson J, Lewis
CM, Mathew CG: Sequence variation, linkage disequilibrium and
Mosor et al. BMC Cancer 2013, 13:457 Page 8 of 8
http://www.biomedcentral.com/1471-2407/13/457association with Crohn’s disease on chromosome 5q31. Genes Immun
2006, 7(5):359–365.
31. Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J,
Heath S, Westervelt P, Watson MA, et al: Acquired copy number alterations
in adult acute myeloid leukemia genomes. Proc Natl Acad Sci USA 2009,
106(31):12950–12955.
32. Uhrhammer N, Delort L, Bignon YJ: Rad50 c.687delT does not contribute
significantly to familial breast cancer in a French population.
Cancer Epidemiol Biomarkers Prev 2009, 18(2):684–685.
33. Cao AY, Hu Z, Yin WJ, Jin W, Shao ZM: Some common mutations of
RAD50 and NBS1 in western populations do not contribute significantly
to Chinese non-BRCA1/2 hereditary breast cancer. Breast Cancer Res Treat
2010, 121(1):247–249.
34. Ciara E, Piekutowska-Abramczuk D, Popowska E, Grajkowska W, Barszcz S,
Perek D, Dembowska-Baginska B, Perek-Polnik M, Kowalewska E, Czajnska A,
et al: Heterozygous germ-line mutations in the NBN gene predispose to
medulloblastoma in pediatric patients. Acta Neuropathol 2010,
119(3):325–334.
35. Nowak J, Mosor M, Nowicka K, Rembowska J, Januszkiewicz D: Is the NBN
gene mutation I171V a potential risk factor for malignant solid tumors in
children? J Pediatr Hematol Oncol 2011, 33(6):e248–e249.
36. Dzikiewicz-Krawczyk A, Mosor M, Januszkiewicz D, Nowak J: Impact of
heterozygous c.657-661del, p.I171V and p.R215W mutations in NBN on
nibrin functions. Mutagenesis 2012, 27(3):337–343.
37. Jiang L, Liang J, Jiang M, Yu X, Zheng J, Liu H, Wu D, Zhou Y: Functional
polymorphisms in the NBS1 gene and acute lymphoblastic leukemia
susceptibility in a Chinese population. Eur J Haematol 2011, 86(3):199–205.
38. Yao F, Fang Y, Chen B, Jin F, Wang S: Association between the NBS1
Glu185Gln polymorphism and breast cancer risk: a meta-analysis.
Tumour Biol 2013, 34(2):1255–1262.
doi:10.1186/1471-2407-13-457
Cite this article as: Mosor et al.: Germline variants in MRE11/RAD50/NBN
complex genes in childhood leukemia. BMC Cancer 2013 13:457.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
